My research investigates collagen-binding receptors on breast cancer cells as potential biomarkers to distinguish harmless early-stage tumours from aggressive ones. Using genetically matched 3D cancer models, the project identifies how receptor activity affects invasion and collagen organization, aiming to reduce overtreatment and support clearer clinical decisions for early breast cancer patients.

This research investigates a novel two-drug therapy for ovarian cancer that kills cancer cells without harming healthy tissues and partially reactivates the suppressed immune system. The PhD work explores how this immune “reawakening” occurs, aiming to identify new strategies to enhance it and create more effective, resistance-proof treatments.